The Process For Off-Shoring Medical Innovation
acroMIS, an International Medical Consulting firm in California, published a series of three articles describing the process for off-shoring and implementation of U.S. medical device innovation in Europe. Free @ http://www.implementation.acromis.com/
Online, September 27, 2010 (Newswire.com) - Just in time for the American College of Surgeons (ACS) 96th annual Clinical Congress, acroMIS, an International Medical Consulting firm in California, published a series of three articles describing the process for off-shoring and implementation of U.S. medical device innovation in Europe.
For the first time at the nation's capital, this year, the ACS Congress is scheduled for October 3-7, 2010, at the Walter E. Washington Convention Center in Washington, DC. In addition to clinical and scientific research, congress topics include the advances in Endoscopic Surgery, Intraluminal, Transluminal, and Combined Laparoscopic-Endoscopic Approaches. U.S. start-up & early-stage companies, and later stage corporations are occupied with the safe introduction of new medical devices in this paradigm-changing field and seek new ways to do so. More than 80 percent of senior device executives participating in a survey indicated that economic policy and regulatory changes are making it more attractive to do business outside the U.S. Not long ago, these executives were thinking they were going to get their products rapidly approved and to market in the U.S. It doesn't happen that rapidly anymore. The U.S. medical device industry is off-shoring its medical innovation and an increasing number of U.S. medical device start-up companies are planning to have their products approved for sale in Europe. The National Venture Capital Association (NVCA) today announced the formation of the Medical Innovation and Competitiveness (MedIC) Coalition with the purpose to address the rising concern that the U.S. is at risk of losing a leadership position in innovation and job creation due to increasing uncertainty in the regulatory and reimbursement processes, healthcare reform implementation and the capital markets.
The acroMIS articles describe the process for medical device implementation in Europe. The first of three articles is titled, "New European markets can bring tangible value to U.S. device companies". The second article of the series is titled "Free Movement Of U.S. Devices Within The European Market" and focuses on a detailed process description about how to implement European CE marking requirements. The third article of the series is titled "European In-country Opportunity Assessment, Commercial Implementation and Business Development of U.S. Medical Innovation" and focuses on the pathway to early clinical uses and commercial success in Europe. The final article of the series also offers a comprehensive list of relevant resources and their websites. All three articles are published by acroMIS LLC of Encinitas, CA. To request a free copy of the first article please send an email to info@acroMIS.com or download it at http://www.implementation.acromis.com/
About acroMIS implementation and development: Our mission at acroMIS is to implement and develop medical device technology in new markets using cost effective and sustainable methods. We offer our services to VC firms & entrepreneurs, start-up & early-stage companies, and later stage corporations. Our clients benefit from our international business development experience and global network of experts.
For more information:
Haio Fauser, (650) 336-8641, hfauser@acroMIS.com.
For more information on our services:
http://www.acromis.com/acroMIS.pdf